- Sorafenib, sold
under the
brand name
Nexavar, is a
kinase inhibitor drug
approved for the
treatment of
primary kidney cancer (advanced
renal cell carcinoma)...
- co-developed and co-marketed with
Bayer and sold
under the
trade name
Nexavar, is a drug
approved in the
United States for the
treatment of advanced...
-
produce a
cheaper and
generic version of Bayer's anti-cancer
medication Nexavar. In the
United States, it
launched influenza medication Tamiflu with marketing...
- Event,
regarding India compulsory license of
Nexavar". 2014-02-07. "Bayer CEO
Marijn Dekkers explains:
Nexavar cancer drug is for "western
patients who can...
-
clots to a
greater extent than some
other classes of
birth control pills.
Nexavar (sorafenib) is a
kinase inhibitor used in the
treatment of
liver cancer...
- finding,
erlotinib has
replaced gefitinib in this setting.
Sorafenib (
Nexavar)
Sunitinib (Sutent)
Dasatinib (Sprycel)
Lapatinib (Tykerb)
Nilotinib (Tasigna)...
-
treatment options include biological therapies such as everolimus, torisel,
nexavar, sutent, and axitinib, the use of
immunotherapy including interferon and...
- interest. This
right was used in 2012, when
Natco was
granted a CL to
produce Nexavar, a
cancer drug. In 2005, a
provision was
added to the new
legislation as...
-
kinase domain as
cancer therapeutic candidates. BAY43-9006 (Sorafenib,
Nexavar) is a V600E
mutant B-Raf and C-Raf
inhibitor approved by the FDA for the...
- 2003
Erlotinib (Tarceva) EGFR
Esophageal cancer,
Glioma 2004
Sorafenib (
Nexavar) Raf, VEGFR, PDGFR, Flt3, KIT
Renal cell
carcinoma 2005
Sunitinib (Sutent)...
